PE, the abbreviation of Private Equity, refers to investing in unlisted companies through private equity funds, obtaining company shares and becoming shareholders.

Pharmaceutical company PE refers to a form in which pharmaceutical companies raise funds through private equity funds and invest in other unlisted pharmaceutical companies or conduct capital operations themselves.

The significance of PE for pharmaceutical companies is to expand the capital base, enhance investment capabilities, and provide more financial support for the company's steady development in the future.

At the same time, pharmaceutical company PEs can also acquire more market shares and R&D resources through mergers and acquisitions of other unlisted pharmaceutical companies or through capital operations, thereby improving corporate competitiveness.

PE of pharmaceutical companies also has risks, such as long capital return cycle, uncertainty of investment goals, and low return on investment.

In addition, pharmaceutical company PEs also need to face the industry's high standards for risk and quality.

Therefore, in the field of PE investment, it is necessary to carefully select high-quality partners.